As a new-type foreign trade service provider driven by dual engines of technology transformation and foreign trade services, HiSiaddi has built a "1+2+3+4=1" service system and can supply hyaluronic acid sourced directly from multiple well-known original manufacturers.
As a R&D-oriented foreign trade service provider, HiSiaddi has repeatedly collaborated with factories on technology conversion and accurately captured market demands to propose formula optimization schemes and application improvement suggestions for hyaluronic acid products. Below is a consulting case of formula optimization for hyaluronic acid products delivered by HiSiaddi.
Please contact HiSiaddi customer service if you require more formula optimization consulting services.
1. Partner Client: DermaMed High-End Medical Aesthetics Pharmaceutical Group, Northern Germany (mid-to-high-end positioning). It mainly produces Class III post-aesthetic procedure dressings, raw liquids for superficial dermal injection filling and sterile salon repair serums. Its products comply with EP European Pharmacopoeia, Germany’s LFBG medical regulations and EU MDR medical device new regulations, supplying over 400 private dermatology hospitals and high-end chain medical aesthetics clinics across Germany. The group purchases 52 tons of pharmaceutical-grade hyaluronic acid annually in three grades: ultra-low molecular weight, medium molecular weight and high molecular weight. It originally purchased pharmaceutical-grade HA from BASF Europe, yet its entire serum & injection raw liquid production line suspended after switching to off-the-shelf raw materials from China’s leading raw material manufacturers in 2025.
2. HiSiaddi’s Role: Chemical foreign trade service provider responsible for raw material traceability, formula debugging, factory production process optimization, directional modification of upstream raw materials and delivery of full-chain technical solutions.
3. Raw Material Category: Fermented injectable sodium hyaluronate (not low-end general daily chemical-grade HA).
1. Severe powder dissolution agglomeration blocking feeding pipelines, cutting production efficiency by 40% Domestic delivered HA powder features disordered particle size distribution and excessive fine powder proportion. When the client’s workshop directly feeds powder into clean water, powder instantly clumps upon contact with water, frequently bridging and blocking negative pressure feeding pipelines. Each batch requires manual crushing of agglomerates, which introduces fine impurities; semi-finished injection raw liquid exceeds particle standards and cannot be filtered and filled.
2. HA molecular degradation during high-temperature homogenization leading to sharp viscosity drop The client’s original European raw materials feature strong heat stability, while domestic raw materials have weak heat and shear resistance. After the workshop’s conventional homogenization at 85℃ with high-speed stirring, HA macromolecular chains break, resulting in an 18% drop in measured molecular weight. Supporting force of filling raw liquid fails to meet standards, viscosity difference within the same batch exceeds limits, and batch consistency spirals out of control.
1. Flocculent precipitation and solution turbidity when compounded with Vitamin C and Niacinamide The client’s mature formula combines HA + L-Ascorbic Acid + Niacinamide complex serums. European original HA features stable buffer systems, while domestic raw materials carry free impurities with excessive pH fluctuation range (5.1~6.7). After compounding, the system suffers acid-base imbalance, causing active substances to flocculate and precipitate white flocs. Serum light transmittance fails standards, with 380kg of semi-finished products scrapped in a single batch.
2. Raw liquid yellowing & oxidation after sealed storage for 1.5~2 months, excessive GSSG oxidation impurities Reduced sulfhydryl groups in HA are prone to oxidation; domestic raw materials carry elevated protein and trace heavy metal residues. After normal-temperature light-proof storage, the liquid gradually turns yellow, with oxidation impurities surging from 0.22% at factory delivery to 1.15%, exceeding the German Pharmacopoeia limit of ≤0.5%. Injectable products face risks of subcutaneous redness and sensitization, making them unfit for European end markets.
The factory’s factory COA only marks national standard purity, lacking itemized data required by the EU for endotoxin, protein residue and molecular weight distribution PD values, hindering the client’s completion of drug filing under Germany’s LFBG regulation and delaying new product launch.
1. Root Causes at Original Raw Material Factory ① Mass production adopts general animal peptone fermentation, with only two-stage rough filtration for refining, leading to elevated protein and trace copper/iron heavy metal residues — the core inducement of oxidative yellowing. ② Fixed enzymatic hydrolysis parameters result in wide molecular weight distribution (PD＞1.45), uneven powder thickness, poor water solubility and high tendency to agglomerate. ③ Lack of precise pH control procedures, with excessive single-batch pH fluctuation at factory delivery and no buffered substrate, resulting in poor compatibility with multi-active compound formulas.
2. Root Causes in Client Formula Design The original formula is adapted to European customized buffered HA, without adjusting chelator and buffer salt dosage for impurity characteristics of domestic raw materials, resulting in excessively low fault tolerance of the formula system.
3. Root Causes in Client Workshop Production Process The client copied European raw material parameters of high temperature and high shear force without adjusting homogenization temperature and stirring speed according to domestic HA’s heat and shear resistance performance.
1. Fermentation & Purification Optimization Coordinate manufacturers to switch to fully plant-based culture medium and eliminate animal peptone; upgrade four-stage ultrafiltration + refined activated carbon impurity removal processes to strictly control protein residue ＜0.01%, single heavy metal ＜0.2ppm and endotoxin ＜0.03EU/mg, cutting off the path of metal ion catalytic oxidation.
2. Powder Granulation Modification Optimization Optimize recrystallization processes to regularize powder particle size and narrow molecular weight distribution to PD＜1.3; add trace food-grade trehalose as anti-agglomeration auxiliary agent before factory delivery to improve cold water dispersibility and eliminate dissolution agglomeration defects at the raw material source.
3. Pre-Buffer Treatment Before Factory Delivery Pre-adjust buffered substrate at factory delivery to lock the pH of 1% aqueous solution within a narrow range of 5.4~5.6, reducing acid-base conflicts in subsequent formula compatibility.
1. Rectification of Salon Repair Serum (HA + Vitamin C + Niacinamide) Formula ① Add compound chelator of Disodium EDTA + Phytic Acid to complex trace heavy metal ions in raw materials; ② Introduce Citric Acid-Sodium Citrate buffer system to fix the final formula pH at 4.2±0.1, falling within the dual stable range of HA and Vitamin C, completely resolving precipitation and turbidity issues; ③ Compound a small amount of natural Vitamin C precursor to enhance system oxidation resistance and extend shelf life.
2. Fine-Tuning of Injection Filling Raw Liquid Formula Reduce inorganic salt dosage in the formula to avoid HA molecular curling and precipitation caused by sudden ionic strength changes; simultaneously replace preservative-free sterile auxiliary materials to match EU injectable raw material specifications.
1. Feeding Process Rectification Cancel one-time full powder addition into water; optimize feeding sequence: pre-disperse HA dry powder with glycerin → slowly sprinkle into purified water at low speed, conduct low-temperature hydration (25~30℃) for 12h before subsequent processes to eliminate agglomeration.
2. Homogenization Temperature Control Optimization Lower homogenization temperature from 85℃ to 55℃, adopt wide-paddle low-speed stirring to reduce mechanical shear force, avoid high-temperature chain scission degradation and stabilize finished product molecular weight and viscosity within tolerance ranges.
3. Storage Control Optimization Store incoming raw materials at constant 20℃ with humidity ＜30% under sealed conditions; use opened raw materials within 24 hours and vacuum re-seal residual raw materials with aluminum foil for preservation.
Coordinate the factory to issue Chinese-English bilingual COAs in accordance with EP European Pharmacopoeia, itemizing full measured data of molecular weight, endotoxin, protein, heavy metals and oxidation impurities; compile English GHS MSDS and SCCS safety assessment reports to help clients complete pre-import filing of raw materials in Germany.
1. Sample Verification: Modified raw material small samples are sent to German SGS for testing; raw liquid shows no yellowing or precipitation after 3 months of accelerated normal-temperature testing. Mass production in the workshop proceeds smoothly without feeding agglomeration, with viscosity and molecular weight fluctuations controlled within the client’s tolerance range.
2. Benefits for Client: 52 tons shipped in 8 batches from Shanghai to Hamburg with zero customs inspection. Three medical beauty products successfully pass German drug filing and are fully launched at cooperating medical aesthetics institutions across Germany. Compared with original imported European raw materials, comprehensive procurement cost drops by 29%, and the client renewed a 60-ton annual procurement order the following year with additional customized demand for cross-linked hyaluronic acid.
3. Benefits for Upstream Factory: Standardized processes for EP Pharmacopoeia-grade customized HA are implemented, this grade achieves a 30% export premium, and the factory expands medical beauty clients in the Netherlands, Austria and other EU countries.
4. Accumulation for HiSiaddi: A standardized technical service system for hyaluronic acid is established: raw material modification → formula optimization → mass production process calibration → cross-border compliance.
Mid-to-high-end medical beauty raw materials in Europe and America are bound by EP Pharmacopoeia and local medical regulations, imposing far stricter requirements on HA purity, impurities and physicochemical stability than domestic national standard off-the-shelf products. Standardized mass-produced domestic HA has natural parameter gaps when matching European formulas, easily triggering mass production failures such as agglomeration, oxidation and compatibility precipitation. Leveraging upstream and downstream technical resources, HiSiaddi eliminates full-chain technical pain points in one go through three linkage measures: modifying raw material indicators upstream, optimizing end formulas midstream and standardizing client production processes downstream, achieving a three-way win-win situation for overseas clients’ cost reduction, factory product upgrading and foreign trade service providers.
Please contact HiSiaddi customer service if you require more formula optimization consulting services.
+86-13120989737 
info@hisiaddi.com 
English
